New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...

With such volatility, SLXN has emerged as one of the most talked-about stocks of the day, creating a buzz in the biotechnology sector. Let’s dive into the details behind this remarkable movement and ...

The findings suggest that "supportive care and management of geriatric vulnerabilities at baseline may improve outcomes and ...

Pancreatic Cancer Action Network Calls for Urgently Needed Research and Funding for Effective Early Detection Strategy and ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

Symptoms of pancreatic cancer can be difficult to spot, but the sooner the patient is diagnosed the better prospects they ...

Baseline geriatric vulnerabilities and QOL scores are associated with survival after chemotherapy in older adults with metastatic pancreatic cancer, researchers found.

Cancer diagnoses are expected to exceed two million in 2025, with approximately 618,120 deaths predicted, according to the ...

The new findings show the cancer mortality rate declined by 34% from 1991 to 2022 in the United States, averting ... Experimental Blood Test for Pancreatic Cancer Undergoing Clinical Development ...

Gastroenterologist Dr. Rohan Mandaliya of The Center for Comprehensive Pancreatic Care at Mercy goes over the risk factors of ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five years after diagnosis; for women it is 14%. In pancreatic cancer ...